This is a working overview of reference standard, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-21 and is reviewed periodically as new material appears.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved in the US, EU and Australia | Sale and import restricted; no licensed product |
| Typical test matrices | Urine, serum, seized powder | Urinary detection window is short |
| Primary identification method | LC-MS/MS against a reference standard | High-resolution mass used for confirmation |
| Data sources in the literature | Small trials, case reports, pharmacovigilance | No registrational trial dataset exists |
| Common marketing names | Melanotan 2, MT-II, MT-2 | Label content may not match declared peptide |
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
=== Tuberous sclerosis complex === Sirolimus also shows promise in treating tuberous sclerosis complex (TSC), a congenital disorder that predisposes those afflicted to benign tumor growth in the brain, heart, kidneys, skin, and other organs. After several studies conclusively linked mTOR inhibitors to remission in TSC tumors, specifically subependymal giant-cell astrocytomas in children and angiomyolipomas in adults, many US doctors began prescribing sirolimus (Wyeth's Rapamune) and everolimus (Novartis's RAD001) to TSC patients off-label. Numerous clinical trials using both rapamycin analogs, involving both children and adults with TSC, are underway in the United States.
SO2 + HO• → HSO3 HSO3 + O2 → SO3 + HO2 SO3 + H2O → H2SO4 Because sulfuric acid reaches supersaturation in the stratosphere, it can nucleate aerosol particles and provide a surface for aerosol growth via condensation and coagulation with other water-sulfuric acid aerosols. This results in the stratospheric aerosol layer.
The uprising may have been significant for the organisational development and strategy of the UDF. Over the course of the first year of the uprising, an internal debate was settled in favour of the front taking on a more expansive role, which would go beyond campaign-based protest and opposition to the Tricameral Parliament. Thus in 1985, the front declared its proposal to move "from mobilisation to organisation" through a programme to strengthen its organisational structures and discipline, including through increased accountability and representation for local affiliates. Similarly, at the grassroots level, by 1986 there was a movement in many black townships to re-establish political discipline, including by persuading students to return to school and subjecting them to the authority of strong local civic associations which included representations for elders. Moreover, historians of South Africa's trade union movement often view the Vaal uprising as an inflection point in the politicisation (or re-politicisation) of the major trade unions. According to Eddie Webster, the November 1984 stay-away marked "the beginning of united mass action between organised labour, students and community organisations". The Charterist Congress of South African Trade Unions was founded in late 1985 and went on to play a crucial role in the Mass Democratic Movement.
Sources: en.wikipedia.org
Russia claimed to have captured the village of Novomykhailivka, Donetsk Oblast, 20 kilometres from Vuhledar. The upper half of the Kharkiv TV Tower was destroyed by a Russian air strike. British intelligence reported that Russian legislator Dmitry Sablin created a new reserve military drone unit called Bars Kaskad to allow VIPs to serve in Ukraine with a reduced risk of "frontline combat". A crowdfunding effort by 50,000 private Slovak citizens raised €3,071,405 in a week to contribute to the Czech initiative to purchase artillery ammunition for Ukraine.
The researchers found correlations between treatment with antipsychotic drugs and lipid metabolism, in both a lipid-class-specific and drug-specific manner, establishing new foundations around the concept that pharmacometabolomics provides powerful tools for enabling detailed mapping of drug effects. Additional studies by the Pharmacometabolomics Research Network enabled mapping in ways not possible before effects of statins, atenolol and aspirin. Totally new insights were gained about effect of these drugs on metabolism and they highlighted pathways implicated in response and side effects.
In 2013, Michael Klare compared in RealClearPolitics tensions between Russia and the West to the ongoing proxy conflict between Saudi Arabia and Iran. Oxford Professor Philip N. Howard argued that a new cold war was being fought via the media, information warfare, and cyberwar. Some observers, including Syrian president Bashar al-Assad, judged the Syrian civil war to be a proxy war between Russia and the United States, and even a "proto-world war". In January 2016, senior UK government officials were reported to have registered their growing fears that "a new cold war" was now unfolding in Europe: "It really is a new Cold War out there. Right across the EU we are seeing alarming evidence of Russian efforts to unpick the fabric of European unity on a whole range of vital strategic issues". In April 2018, relations deteriorated over a potential US-led military strike in Middle East after the Douma chemical attack in Syria, which was attributed to the Syrian Army by rebel forces in Douma, and poisoning of the Skripals in the UK. The secretary-general of the United Nations, António Guterres, told a meeting of the UN Security Council that "the Cold War was back with a vengeance". He suggested the dangers were even greater, as the safeguards that existed to manage such a crisis "no longer seem to be present". Dmitri Trenin supported Guterres' statement, but added that it began in 2014 and had been intensifying since, resulting in US-led strikes on the Syrian government on 13 April 2018.
== History == Prior to being domesticated, dogs, being canines, fended for themselves and survived on a carnivorous diet. After adapting them for protection, work, and companionship, people began to care at least in part for their nutritional needs. The historic record of this changing approach dates back at least 2,000 years. In 37 BCE, Virgil talks about the feeding of dogs in his Bucolics:
Sources: en.wikipedia.org
Regulatory treatment varies by country. In the United States, the European Union and Australia it is an unapproved drug and its sale is restricted, while some other jurisdictions list it as prescription-only or controlled. The applicable rules depend on the country of import.
Reversed-phase LC-MS/MS is the usual approach for both identification and quantitation. High-resolution mass spectrometry and peptide mapping serve as confirmatory methods. Immunoassays are rarely used alone because of cross-reactivity.
Published testing of seized and purchased samples frequently reports discrepancies between declared and measured peptide content. Counter-ion content and residual solvents add further variation. Independent analysis is the only way to confirm composition.
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.